Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 12:40PM GMT
Release Date Price: $9.65 (-2.05%)
Kristen Kluska
Cantor Fitzgerald, L.P. - Analyst

Hello, everyone. I'm Kristen Kluska, one of the biotechnology analyst at Cantor. It's my pleasure to host Amicus Therapeutics today, which is a company that I'm covering. And joining me on this fireside chat is John Crowley, the Chairman and CEO. Thank you so much for joining us and for being in our conference today.

John Crowley
Amicus Therapeutics, Inc. - Chairman of the Board, CEO

Yes, Kristen, good morning. Thank you for having me.

Questions & Answers

Kristen Kluska
Cantor Fitzgerald, L.P. - Analyst

Great. So, I'll start the focus of questions on AT-GAA for Pompe disease, especially considering you just announced the FDA acceptance of your filings yesterday. I think it would be helpful to first contextualize the current market centered around current standard of care, Lumizyme. While patients may start treatments at different times of their life at different levels of severity, could you please touch on the trends that have been observed with this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot